Richard A. Rosenbloom

Carbiotix is an award winning pre-clinical stage therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases.Carbiotix was founded in 2014 based on four years of research through the Department of Biotechnology at LundUniversity and the Antidiabetic Food Centre (AFC) in Lund, Sweden. In 2015, the company’s second-generation soluble fiber AXOS was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US. In 2017, Carbiotix began development of its low-cost gut health testing platform and in 2018 launched the platform along with commencing a 600-person gut health study. In 2019, the company began to leverage data from its low-cost gut health testing platform to ramp up therapeutic development activities in line with its long-term strategy to create microbiome modulators based on its proprietary soluble fiber, isolated strains and novel delivery mechanisms.